STAG2 and myelodysplastic syndrome: Mutations in the STAG2 gene occur in 6-9% of patients with MDS, about 10% of patients with CMML and 1–6% of patients with AML, and are associated with an unfavorable prognosis in MDS and AML patients [15–18].